Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 19 art units • 19 examiners • 0 of 19 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
The Board of Regents of the University of Nebraska currently has 20 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 20 actions are distributed across 20 distinct examiners and 20 distinct art units. This distribution indicates a fragmented prosecution landscape where no single examiner or department holds a concentration of the portfolio. The presence of 20 distinct examiners suggests that each pending matter is being evaluated through a unique individual lens.
Thomas S. Fix is identified as the busiest examiner with 1 pending action, which is consistent with the distribution across the 20 distinct examiners. This level of dispersion requires practitioners to manage 20 unique examiner relationships and navigate 20 different art units simultaneously. The involvement of 20 distinct art units implies a broad range of biological and pharmaceutical technologies being prosecuted, as each case is situated in a different technical subgroup at the USPTO. Such a diverse distribution prevents the application of a single departmental strategy across the 20 pending office actions. Each of the 20 pending matters is handled as an independent case without examiner or art unit overlap.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (16%) |
| §103 only | 10 (53%) |
| Multi-statute (no §101) | 5 (26%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIX, THOMAS S | 1 | 72.0% | +16.5% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| DUNN, MCKENZIE A | 1 | 54.2% | +57.3% |
| SUN, CAITLYN MINGYUN | 1 | 63.7% | +11.8% |
| DIETRICH, JOSEPH M | 1 | 81.1% | +8.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493925 | SYSTEMS AND METHODS FOR TREATING AND INHIBITING WOUND INFECTIONS | DIETRICH, JOSEPH M | 112d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18386798 | MULTIFUNCTIONAL SOFT BIOELECTRONICS | SUN, CAITLYN MINGYUN | 24d overdue |
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | ALLEY, GENEVIEVE S | 17d overdue |
| 19210517 | SINGLE-ARM ROBOTIC DEVICE WITH COMPACT JOINT DESIGN AND RELATED SYSTEMS AND METHODS | FIX, THOMAS S | — |
| 18987189 | GROWTH FACTOR LOADED NANOFIBERS AND METHODS OF USE THEREOF | DAVIS, BRIAN J | — |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | — |
| 18711139 | NOVEL INHIBITORS OF CLAUDIN-1 FOR THERAPEUTIC INTERVENTIONS | AGGARWAL, SAHIL CHANDER | — |
| 18560365 | NF-KB AS BIOMARKER FOR ASSESSING TREATMENT EFFICACY IN PARKINSON'S DISEASE | DUNN, MCKENZIE A | — |
| 18469022 | COMPUTATIONAL SYSTEM AND METHOD FOR DIAGNOSIS, PROGNOSIS, AND THERAPEUTICS OF CANCER PATIENTS USING SPATIAL-TEMPORAL TISSUE ARCHITECTURAL PROPERTIES | BAILEY, STEVEN WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18386798 | MULTIFUNCTIONAL SOFT BIOELECTRONICS | SUN, CAITLYN MINGYUN | 24d overdue |
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | ALLEY, GENEVIEVE S | 17d overdue |
| 18699799 | REFILLABLE TISSUE ENGINEERED SCAFFOLDS | PACKARD, BENJAMIN J | 10d overdue |
| 19210517 | SINGLE-ARM ROBOTIC DEVICE WITH COMPACT JOINT DESIGN AND RELATED SYSTEMS AND METHODS | FIX, THOMAS S | — |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | — |
| 18622241 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | RODRIGUEZ, RAYNA B | — |
| 18560365 | NF-KB AS BIOMARKER FOR ASSESSING TREATMENT EFFICACY IN PARKINSON'S DISEASE | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 3618 | 1 |
| 1614 | 1 |
| 1615 | 1 |
| 1623 | 1 |
| 1612 | 1 |
| 1628 | 1 |
| 1617 | 1 |
| 1678 | 1 |
| 1795 | 1 |
| 3796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19210517 | SINGLE-ARM ROBOTIC DEVICE WITH COMPACT JOINT DESIGN AND RELATED SYSTEMS AND METHODS | FIX, THOMAS S | 3618 | §101DP | Final Rejection | — | Pending | May 16, 2025 |
| 18987189 | GROWTH FACTOR LOADED NANOFIBERS AND METHODS OF USE THEREOF | DAVIS, BRIAN J | 1614 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | 1615 | §102§103 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18711139 | NOVEL INHIBITORS OF CLAUDIN-1 FOR THERAPEUTIC INTERVENTIONS | AGGARWAL, SAHIL CHANDER | 1623 | §102§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18699799 | REFILLABLE TISSUE ENGINEERED SCAFFOLDS | PACKARD, BENJAMIN J | 1612 | §103 | Non-Final OA | 10d overdue | Pending | Apr 09, 2024 |
| 18622241 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | RODRIGUEZ, RAYNA B | 1628 | §103 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | ALLEY, GENEVIEVE S | 1617 | §102§103§112 | Final Rejection | 17d overdue | Pending | Mar 08, 2024 |
| 18560365 | NF-KB AS BIOMARKER FOR ASSESSING TREATMENT EFFICACY IN PARKINSON'S DISEASE | DUNN, MCKENZIE A | 1678 | §101§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18386798 | MULTIFUNCTIONAL SOFT BIOELECTRONICS | SUN, CAITLYN MINGYUN | 1795 | §103§112 | Non-Final OA | 24d overdue | Pending | Nov 03, 2023 |
| 18493925 | SYSTEMS AND METHODS FOR TREATING AND INHIBITING WOUND INFECTIONS | DIETRICH, JOSEPH M | 3796 | §103 | Non-Final OA | 112d overdue | Pending | Oct 25, 2023 |
| 18469022 | COMPUTATIONAL SYSTEM AND METHOD FOR DIAGNOSIS, PROGNOSIS, AND THERAPEUTICS OF CANCER PATIENTS USING SPATIAL-TEMPORAL TISSUE ARCHITECTURAL PROPERTIES | BAILEY, STEVEN WILLIAM | 1687 | §101§102§103 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18550828 | LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF | RYAN, DOUGLAS CHARLES | 1635 | §103Other | Final Rejection | — | Pending | Sep 15, 2023 |
| 18281911 | CATHETER PLACEMENT DEVICES | GRAY, PHILLIP A | 3783 | §103 | Final Rejection | — | Pending | Sep 13, 2023 |
| 18278865 | Antimicrobial Peptides | JAUHARI, SACHI | 1654 | §103Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18197905 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | BAEK, BONG-SOOK | 1611 | Other | Final Rejection | — | Pending | May 16, 2023 |
| 17905407 | CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 28d | Pending | Aug 31, 2022 |
| 17681541 | LIGHTWEIGHT LIQUID METAL EMBEDDED ELASTOMER COMPOSITE | LING, DORIS | 1764 | §103 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17309435 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 45d overdue | Pending | May 27, 2021 |
| 17051097 | STENT-GRAFT | PELLEGRINO, BRIAN E | 3799 | §103 | Final Rejection | — | Pending | Oct 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBoard of Regents of the University of Nebraska has 19 pending office actions as of October 2026, spread across 19 art units and 19 examiners.
Thomas S Fix has the most, with 1 of Board of Regents of the University of Nebraska's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
